Migraine with aura from pathophysiology to treatment: Therapeutic strategies

Giovinavi D'Andrea, G. Allais, L. Grazzi, L. Fumagalli

Research output: Contribution to journalArticlepeer-review


Migraine with aura (MwA) sufferers, at times, need specific treatments. This is the case when the auras are frequent, prolonged and cause anxiety and distress. Abnormal release of glutamate, that may trigger auras, and abnormal platelet behaviour, that constitute a possible predisposing factor to MwA, may be possible targets for MwA specific prophylactic therapy. Here we present results obtained by using lamotrigine, an agent known to inhibit glutamate release, and picotamide, an antiplatelet drug. Both drugs significantly reduced, in two open label trials, the frequency and the duration of auras. In comparison with lamotrigine, the therapy with picotamide may offer some advantages, such as the use of the therapeutical dose from the first day of treatment (lamotrigine needs one month to reach such a dose) and the possibility to prevent cerebral ischaemic events and migraine stroke, a rare but severe complication of MwA attacks.

Original languageEnglish
JournalNeurological Sciences
Issue numberSUPPL. 2
Publication statusPublished - May 2005


  • Lamotrigine
  • Migraine with aura
  • Neuronal hyperexcitability
  • Picotamide
  • Platelet activation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology


Dive into the research topics of 'Migraine with aura from pathophysiology to treatment: Therapeutic strategies'. Together they form a unique fingerprint.

Cite this